Echinocandin antifungal drug resistance in candida species: A cause for concern?

Current Infectious Disease Reports

Volumn 12, Issue 6, 2010, Pages 437-443

  Sanguinetti, Maurizio ^a   Posteraro, Patrizia ^b   Posteraro, Brunella ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

Author keywords

Breakthrough infection; Candida species; Echinocandin drugs; FKS mutation; Invasive candidiasis; Resistance mechanism; Treatment failure

Indexed keywords

1,3 BETA GLUCAN SYNTHASE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CALCINEURIN INHIBITOR; CASPOFUNGIN; CHITIN; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; CANDIDA; CANDIDEMIA; CANDIDIASIS; CELL WALL; CLINICAL TRIAL; DRUG MECHANISM; ESOPHAGUS CANDIDIASIS; FUNGICIDAL ACTIVITY; HUMAN; INVASIVE CANDIDIASIS; NONHUMAN; POINT MUTATION; REVIEW;

EID: 77958184622     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-010-0131-2     Document Type: Review

References (49)

1. JB Anderson 2005 Evolution of antifungal-drug resistance: mechanisms and pathogen fitness Nat Rev Microbiol 3 547 556 1:CAS:528:DC%2BD2MXlslWhuro%3D 10.1038/nrmicro1179 15953931 (Pubitemid 40903878)
2. PO Wainright G Hinkle ML Sogin SK Stickel 1993 Monophyletic origins of the metazoa: an evolutionary link with fungi Science 260 340 342 1:STN:280:DyaK3s3islSnsw%3D%3D 10.1126/science.8469985 8469985
3. SC Chen TC Sorrell 2007 Antifungal agents Med J Aust 187 404 409 17908006
4. AC Pasqualotto DW Denning 2008 New and emerging treatments for fungal infections J Antimicrob Chemother 61 i19 i30 1:CAS:528:DC%2BD1cXhs1CqsLw%3D 10.1093/jac/dkm428 18063600
5. AM Bal 2010 The echinocandins: three useful choices or three too many? Int J Antimicrob Agents 35 13 18 1:CAS:528:DC%2BD1MXhsFanur3K 10.1016/j.ijantimicag.2009.09.011 19942413
6. AJ Reese A Yoneda JA Breger, et al. 2007 Loss of cell wall alpha (1-3) glucan affects Cryptococcus neoformans from ultrastructure to virulence Mol Microbiol 63 1385 1398 1:CAS:528:DC%2BD2sXjsVyqtb0%3D 10.1111/j.1365-2958.2006. 05551.x 17244196
7. DW Denning 2003 Echinocandin antifungal drugs Lancet 362 1142 1151 1:CAS:528:DC%2BD3sXnvVKrtbo%3D 10.1016/S0140-6736(03)14472-8 14550704 (Pubitemid 37222342)
8. J Maertens M Boogaerts 2003 Caspofungin in the treatment of candidosis and aspergillosis Int J Infect Dis 7 94 101 10.1016/S1201-9712(03)90003-8 12839709 (Pubitemid 36753513)
9. JC Bowman PS Hicks MB Kurtz, et al. 2002 The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro Antimicrob Agents Chemother 46 3001 3012 1:CAS:528:DC%2BD38Xmtl2ktb8%3D 10.1128/AAC.46.9.3001-3012.2002 12183260
10. P Muñoz N Singh E Bouza 2006 Treatment of solid organ transplant patients with invasive fungal infections: should a combination of antifungal drugs be used? Curr Opin Infect Dis 19 365 370 10.1097/01.qco.0000235164.70678. 97 16804385 (Pubitemid 43982510)
11. MA Pfaller DJ Diekema L Ostrosky-Zeichner, et al. 2008 Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints J Clin Microbiol 46 2620 2629 1:CAS:528:DC%2BD1cXhtVyms7zI 10.1128/JCM.00566-08 18579718
12. P Paderu G Garcia-Effron S Balashov, et al. 2007 Serum differentially alters the antifungal properties of echinocandin drugs Antimicrob Agents Chemother 51 2253 2256 1:CAS:528:DC%2BD2sXmtlKrt7s%3D 10.1128/AAC.01536-06 17420211 (Pubitemid 46903131)
13. DS Perlin 2007 Resistance to echinocandin-class antifungal drugs Drug Resist Updat 10 121 130 1:CAS:528:DC%2BD2sXnslWksr0%3D 10.1016/j.drup.2007.04. 002 17569573 (Pubitemid 47031054)
14. MA Pfaller L Boyken RJ Hollis, et al. 2008 In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance J Clin Microbiol 46 150 156 1:CAS:528:DC%2BD1cXhs1aqtb8%3D 10.1128/JCM.01901-07 18032613
15. S Krishnan-Natesan EK Manavathu JL Cutright PH Chandrasekar 2010 Efficacy of anidulafungin, caspofungin and fluconazole in the early phase of infection in a neutropenic murine invasive candidiasis model Int J Antimicrob Agents 36 33 36 1:CAS:528:DC%2BC3cXmsVGrsbo%3D 10.1016/j.ijantimicag.2010.02.020 20400270
16. PG Pappas CA Kauffman D Andes, et al. 2009 Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America Clin Infect Dis 48 503 535 1:CAS:528:DC%2BD1MXjslantLY%3D 10.1086/596757 19191635
17. J Mora-Duarte R Betts C Rotstein, et al. 2002 Comparison of caspofungin and amphotericin B for invasive candidiasis N Engl J Med 347 2020 2029 1:CAS:528:DC%2BD38Xps1Ojtbs%3D 10.1056/NEJMoa021585 12490683 (Pubitemid 35461658)
18. ER Kuse P Chetchotisakd CA da Cunha, et al. 2007 Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: A phase III randomised double-blind trial Lancet 369 1519 1527 1:CAS:528: DC%2BD2sXkvFGmt7c%3D 10.1016/S0140-6736(07)60605-9 17482982 (Pubitemid 46670281)
19. AC Reboli C Rotstein PG Pappas, et al. 2007 Anidulafungin Study Group: Anidulafungin versus fluconazole for invasive candidiasis N Engl J Med 356 2472 2482 1:CAS:528:DC%2BD2sXms1Sis7w%3D 10.1056/NEJMoa066906 17568028
20. L Pagano L Fianchi R Fanci, et al. 2010 Caspofungin for the treatment of candidaemia in patients with haematological malignancies Clin Microbiol Infect 16 298 301 1:CAS:528:DC%2BC3cXktlylu70%3D 10.1111/j.1469-0691.2009.02832.x 19549221
21. TJ Walsh H Teppler GR Donowitz, et al. 2004 Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia N Engl J Med 351 1391 1402 1:CAS:528:DC%2BD2cXotVOrsro%3D 10.1056/NEJMoa040446 15459300 (Pubitemid 39288165)
22. JA Maertens L Madero AF Reilly, et al. 2010 A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia Pediatr Infect Dis J 29 415 420 10.1097/INF.0b013e3181da2171 20431381
23. LA Walker NA Gow CA Munro 2010 Fungal echinocandin resistance Fungal Genet Biol 47 117 126 1:CAS:528:DC%2BC3cXnsFWqtw%3D%3D 10.1016/j.fgb.2009.09.003 19770064
24. HY Sun N Singh 2010 Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review Int J Antimicrob Agents 35 211 218 1:CAS:528:DC%2BC3cXotVeitA%3D%3D 10.1016/j.ijantimicag.2009.09.020 20036518
25. S Park R Kelly JN Kahn, et al. 2005 Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates Antimicrob Agents Chemother 49 3264 3273 1:CAS:528:DC%2BD2MXntFChtb8%3D 10.1128/AAC.49.8.3264-3273.2005 16048935 (Pubitemid 41060570)
26. CM Douglas 2001 Fungal beta(1, 3)-D-glucan synthesis Med Mycol 39 55 66 1:CAS:528:DC%2BD38XltlGgug%3D%3D 11800269
27. SP Bachmann TF Patterson JL López-Ribot 2002 In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance J Clin Microbiol 40 2228 2230 1:CAS:528:DC%2BD38XltFOntbs%3D 10.1128/JCM.40.6.2228-2230.2002 12037093 (Pubitemid 34596413)
28. B Posteraro M Sanguinetti B Fiori, et al. 2006 Caspofungin activity against clinical isolates of azole cross-resistant Candida glabrata overexpressing efflux pump genes J Antimicrob Chemother 58 458 461 1:CAS:528:DC%2BD28Xotl2ltrw%3D 10.1093/jac/dkl237 16757500 (Pubitemid 44294967)
29. SV Balashov S Park DS Perlin 2006 Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1 Antimicrob Agents Chemother 50 2058 2063 1:CAS:528: DC%2BD28XlsVOitbg%3D 10.1128/AAC.01653-05 16723566 (Pubitemid 43807526)
30. S Katiyar M Pfaller T Edlind 2006 Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility Antimicrob Agents Chemother 50 2892 2894 1:CAS:528:DC%2BD28XotlehtL0%3D 10.1128/AAC.00349-06 16870797 (Pubitemid 44198725)
31. G Garcia-Effron S Lee S Park, et al. 2009 Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1, 3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint Antimicrob Agents Chemother 53 3690 3699 1:CAS:528:DC%2BD1MXhtFCjsr7I 10.1128/AAC.00443-09 19546367
32. G Garcia-Effron S Park DS Perlin 2009 Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints Antimicrob Agents Chemother 53 112 122 1:CAS:528:DC%2BD1MXhs1Kks78%3D 10.1128/AAC.01162-08 18955538
33. DS Perlin 2009 Antifungal drug resistance: do molecular methods provide a way forward? Curr Opin Infect Dis 22 568 573 1:CAS:528:DC%2BD1MXhtlensrvN 10.1097/QCO.0b013e3283321ce5 19741524
34. G Garcia-Effron SK Katiyar S Park, et al. 2008 A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility Antimicrob Agents Chemother 52 2305 2312 1:CAS:528: DC%2BD1cXot1Oitrg%3D 10.1128/AAC.00262-08 18443110 (Pubitemid 351915657)
35. N Kartsonis J Killar L Mixson, et al. 2005 Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome Antimicrob Agents Chemother 49 3616 3623 1:CAS:528:DC%2BD2MXpvFKlt7g%3D 10.1128/AAC.49.9.3616- 3623.2005 16127030 (Pubitemid 41233008)
36. DA Stevens M Espiritu R Parmar 2004 Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations Antimicrob Agents Chemother 48 3407 3411 1:CAS:528:DC%2BD2cXnsVehs74%3D 10.1128/AAC.48.9.3407-3411.2004 15328104 (Pubitemid 39129338)
37. LA Walker CA Munro I de Bruijn, et al. 2008 Stimulation of chitin synthesis rescues Candida albicans from echinocandins PLoS Pathog 4 e1000040 10.1371/journal.ppat.1000040 18389063 (Pubitemid 351631083)
38. CA Munro S Selvaggini I de Bruijn, et al. 2007 The PKC, HOG and Ca2+ signalling pathways co-ordinately regulate chitin synthesis in Candida albicans Mol Microbiol 63 1399 1413 1:CAS:528:DC%2BD2sXjsVyqtbo%3D 10.1111/j.1365-2958. 2007.05588.x 17302816
39. SD Singh N Robbins AK Zaas, et al. 2009 Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin PLoS Pathog 5 e1000532 10.1371/journal.ppat.1000532 19649312
40. WJ Steinbach JL Reedy RA Cramer Jr, et al. 2007 Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections Nat Rev Microbiol 5 418 430 1:CAS:528:DC%2BD2sXltlWjsr0%3D 10.1038/nrmicro1680 17505522 (Pubitemid 46780079)
41. CF Hoehamer ED Cummings GM Hilliard PD Rogers 2010 Changes in the proteome of Candida albicans in response to azole, polyene, and echinocandin antifungal agents Antimicrob Agents Chemother 54 1655 1664 1:CAS:528: DC%2BC3cXmtFemtbc%3D 10.1128/AAC.00756-09 20145080
42. A Safdar DS Perlin D Armstrong 2002 Hematogenous infections due to Candida parapsilosis: changing trends in fungemic patients at a comprehensive cancer center during the last four decades Diagn Microbiol Infect Dis 44 11 16 10.1016/S0732-8893(02)00423-6 12376025
43. CD Pfeiffer G Garcia-Effron AK Zaas, et al. 2010 Breakthrough invasive candidiasis in patients on micafungin J Clin Microbiol 48 2373 2380 1:CAS:528:DC%2BC3cXhtVaktb7L 10.1128/JCM.02390-09 20421445
44. N Kabbara C Lacroix R Peffault de Latour, et al. 2008 Breakthrough C. parapsilosis and C. guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy Haematologica 93 639 640 1:CAS:528:DC%2BD1cXhsVSiu7vM 10.3324/haematol.11149 18379015 (Pubitemid 351536400)
45. ZA Kanafani JR Perfect 2008 Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact Clin Infect Dis 46 120 128 10.1086/524071 18171227 (Pubitemid 351263573)
46. AL Lazzell AK Chaturvedi CG Pierce, et al. 2009 Treatment and prevention of Candida albicans biofilms with caspofungin in a novel central venous catheter murine model of candidiasis J Antimicrob Chemother 64 567 570 1:CAS:528:DC%2BD1MXhtVWju7jK 10.1093/jac/dkp242 19584104
47. F Chapeland-Leclerc C Hennequin N Papon, et al. 2010 Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient Antimicrob Agents Chemother 54 1360 1362 1:CAS:528:DC%2BC3cXjtFWqtL4%3D 10.1128/AAC.01138-09 20038613
48. M Krogh-Madsen MC Arendrup L Heslet JD Knudsen 2006 Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient Clin Infect Dis 42 938 944 1:CAS:528:DC%2BD28Xjtlels7g%3D 10.1086/500939 16511756
49. S Hodgetts L Nooney R Al-Akeel, et al. 2008 Efungumab and caspofungin: pre-clinical data supporting synergy J Antimicrob Chemother 61 1132 1139 1:CAS:528:DC%2BD1cXksF2ltr4%3D 10.1093/jac/dkn075 18299636 (Pubitemid 351524461)